ציין מניה או מטבע קריפטוגרפי בשורת החיפוש כדי לקבל סיכום
Sopharma AD
SPHSopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. The company operates through Production of Pharmaceutical Products; Distribution of Pharmaceutical Products (Goods); and Others. It offers Carsil to treat liver disease; Tempalgin and Analgin, a painkiller; Tabex, drug used for smoking secession; Tribestan, drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin, used for diseases of the peripheral nervous system; Methylprednisolon, for severe allergies and life-threatening conditions; Vitamin C; Valeriana, used to reduce the stress; and medical devices, such as gauzes, compresses, and dressing. The company also provides food supplements; medicinal cosmetics, including plasters, bandages, and sanitary-hygiene products focused; and prescription medicines, on the counter products, and veterinary products. In addition, the company distributes pharmaceuticals, medical supplies, sanitary materials, vitamins, food supplements, and cosmetics; and provides contract manufacturing services; packaging services; and product development services. Further, it is involved in trading of food supplements; secondary packaging services for pharmaceutical products and real estate leases; trades, transports, and packages radioactive materials and nuclear equipment for medicinal use, household electronics, and electrical equipment; purchases, grows, produces, and trades in herbs and medicinal plant; and provision of public opinion research services. Additionally, the company engages in the offline and online retail trade of medicinal products and medical equipment; production of non-medicinal, and other products; and franchising, know-how, and rental of properties, as well as in trading, consulting, and other activities. Sopharma AD was founded in 1933 and is headquartered in Sofia, Bulgaria. Address: 16 Iliensko shosse street, Sofia, Bulgaria, 1220
Analytics
מחיר יעד של וול סטריט
17.15 PLNיחס רווח למחיר
12.3529תשואת דיבידנד
19.77 %השנה הנוכחית
שנה שעברה
רבעון נוכחי
רבע אחרון
השנה הנוכחית
שנה שעברה
רבעון נוכחי
רבע אחרון
דמויות מפתח SPH
ניתוח דיבידנדים SPH
גידול דיבידנד במשך 5 שנים
848 %צמיחה מתמשכת
2 שניםיחס תשלום ממוצע של 5 שנים
105 %היסטוריית דיבידנדים SPH
שווי מניות SPH
פיננסיים SPH
תוצאות | 2019 | דינמיקה |